4320 Forest Park Avenue
About ImmunoPhotonicsImmunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.
Founder and CEO: Tomas Hode, PhD
COO Lu Alleruzzo, MBA
CDO (Chief Drug Dev. Officer): Joe Raker, PhD
Tweets by Immunophotonics
2 articles with ImmunoPhotonics
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy